Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.
A low-cost, group-delivered lifestyle intervention is associated with a significantly lower risk for progression to type 2 diabetes among high-risk individuals.
Investigators evaluated whether the effects of SGLT2 inhibitors on cardiovascular, kidney and mortality outcomes are the same with and without concomitant metformin use.
An intensive lifestyle intervention was found to be associated with a significant loss of fat mass and lean mass in adults with type 2 diabetes.
About one in four U.S. adults (26.4 percent) with diabetes meet the combined goals for preventing or delaying complications of diabetes.
This study evaluated risk for type 2 diabetes among more than 1 million adolescents in Israel with and without nonalcoholic fatty liver disease.
Evidence suggests that a class of drugs used to treat HIV and hepatitis B can reduce a patient’s risk for developing type 2 diabetes.
Atrasentan outperformed both avosentan and bosentan for renoprotection in patients with type 2 diabetic kidney disease.
In the BETonMACE trial, CKD patients with type 2 diabetes who recently experienced acute coronary syndrome who received apabetalone had a significant 50% reduction in the risk for major cardiovascular events compared with placebo.
Finerenone vs placebo added to standard therapy was associated with a significant 18% reduction in the risk for major adverse kidney events in patients with both chronic kidney disease and type 2 diabetes mellitus.